Covered recipient · General Payments record
KATHERINE B WINDHAM
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$2,626.47
- Reported across 147 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $315.42 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $81.89 | 4 |
| GlaxoSmithKline, LLC. | $42.92 | 2 |
| Biosense Webster, Inc. | $40.01 | 1 |
| Lilly USA, LLC | $35.36 | 2 |
| Amgen Inc. | $26.86 | 1 |
| Novo Nordisk AS | $21.90 | 1 |
| Phathom Pharmaceuticals, Inc. | $18.01 | 1 |
| Exact Sciences Corporation | $17.61 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $17.35 | 1 |
| Mylan Specialty L.P. | $13.51 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $26.86 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111740560 | CMS |
| Biosense Webster, Inc. | $40.01 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1077653746 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $17.35 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118243906 | CMS |
| Exact Sciences Corporation | $17.61 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114951879 | CMS |
| GlaxoSmithKline, LLC. | $18.81 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116100336 | CMS |
| GlaxoSmithKline, LLC. | $24.11 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116128712 | CMS |
| Lilly USA, LLC | $15.87 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135076533 | CMS |
| Lilly USA, LLC | $19.49 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135119563 | CMS |
| Mylan Specialty L.P. | $13.51 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147320281 | CMS |
| Novo Nordisk Inc | $21.90 | 03/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097007132 | CMS |
| PFIZER INC. | $23.94 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131670814 | CMS |
| PFIZER INC. | $16.66 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131888384 | CMS |
| PFIZER INC. | $18.92 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131879493 | CMS |
| PFIZER INC. | $22.37 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132087728 | CMS |
| Phathom Pharmaceuticals, Inc. | $18.01 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151139861 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.